PBYI Q3 2023 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$311M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$56M-1.7% YoY

Gross Profit

$43M76.3% margin

Operating Income

$9M15.3% margin

Net Income

$6M10.3% margin

EPS (Diluted)

$0.12

QoQ Revenue Growth

+2.8%

Cash Flow

Operating Cash Flow

$11M

Free Cash Flow

$11M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$204M

Total Liabilities

$165M

Stockholders' Equity

$39M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$56M	$57M	-1.7%
Gross Profit	$43M	$45M	-4.0%
Operating Income	$9M	$2M	+258.8%
Net Income	$6M	-$360,000	+1710.0%

Revenue Segments

Product

$52M92%

Royalty

$5M8%